Intelligent Bio Solutions (INBS) Announces Proposed Public Offering of Common Stock

Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”) a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it is commencing an underwritten public offering of shares of its common stock. All of the shares of common stock are being offered by Intelligent Bio Solutions Inc. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Ladenburg Thalmann & Co. Inc. is acting as the sole bookrunning manager for the offering.

The offering is being made pursuant to a shelf registration statement filed with the Securities and Exchange Commission (“SEC”) on April 8, 2022, and declared effective by the SEC on April 20, 2022.

You May Also Be Interested In

• ONAR Holding regains SEC reporting status, posts revenue gains
• Zimmer Biomet names Chintan Desai Asia Pacific president
• Zoetis agrees to acquire veterinary teleradiology platform VitalRADS